Valion Bio holds special shareholder meeting
VBIO•Valion Bio shareholders authorized a potential 1-for-2 to 1-for-12 reverse stock split and approved adding 272,000 common shares to its equity incentive plan.
1. Shareholder approvals
At a special meeting on November 12, 2026, shareholders authorized the board to implement a reverse stock split ranging from 1-for-2 to 1-for-12 within 12 months of approval. They also approved adding 272,000 common shares to the Amended and Restated 2021 Equity Incentive Plan; the amendment took effect upon approval.




